Supporters and Exhibitors
CoBrCa would like to thank the supporters. It is with the support of the industry that CoBrCa can continue in its mission to promote research and education and to disseminate new knowledge
Click on the logo to find out more about the company!
Platinum Supporters
 |
TBA |
Gold Supporter
 |
Silver Supporters
 |
 |
Bronze Supporters
 |
 |
 |
 |
Exhibitors (Main Exhibition Area)
 |
|
 |
 |
|
|
 |
|
|
 |
 |
|
 |
 |
|
Exhibitors (Poster Area)
 |
Veracyte is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, our exclusive license to a best-in-class diagnostics instrument (the nCounter Analysis System) positions us to deliver our tests to patients worldwide through laboratories that can perform them locally. Veracyte is based in South San Francisco, California.
For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
Exact Sciences is a leading, global cancer diagnostics company. From early detection to diagnosis and treatment guidance, the company is offering and further developing a suite of tests to enable personalised care at all stages of the disease. In early breast cancer, the Oncotype DX® test is the only test validated to identify patients likely to benefit from chemotherapy.
For more information, please visit https://www.exactsciences.com.
For more information, please visit https://www.exactsciences.com.
GC AESTHETICS®
The QUALITY you Expect
The OPTIONS you Need
The PEACE OF MIND you Demand
GC Aesthetics® is an established global medical device company focused on Aesthetic, Revision and Reconstruction procedures. With more than 40 years of experience, surgeons and patients in more than 70 countries with systems in place to ensure the safety of our products through pre-clinical testing, clinical studies and excellent global post-market surveillance use GCA®.
GCA® is A Confident Choice for Life™ supported by a 10-year prospective and multi-centric clinical study and an average of 17 years of extended long-term high patient satisfaction data. We provide the most comprehensive implant portfolio in the industry with breast, face, body implants and skin expanders to give surgeons quality surgical options.
Much more than a European manufacturer of high-quality implants, we are proud to support our surgeons and patients by integrating and developing solutions that are designed to support the best outcome for women´s breast enhancement journey.
A Confident Choice for Life™
For more information, please visit https://www.gcaesthetics.com/
The QUALITY you Expect
The OPTIONS you Need
The PEACE OF MIND you Demand
GC Aesthetics® is an established global medical device company focused on Aesthetic, Revision and Reconstruction procedures. With more than 40 years of experience, surgeons and patients in more than 70 countries with systems in place to ensure the safety of our products through pre-clinical testing, clinical studies and excellent global post-market surveillance use GCA®.
GCA® is A Confident Choice for Life™ supported by a 10-year prospective and multi-centric clinical study and an average of 17 years of extended long-term high patient satisfaction data. We provide the most comprehensive implant portfolio in the industry with breast, face, body implants and skin expanders to give surgeons quality surgical options.
Much more than a European manufacturer of high-quality implants, we are proud to support our surgeons and patients by integrating and developing solutions that are designed to support the best outcome for women´s breast enhancement journey.
A Confident Choice for Life™
For more information, please visit https://www.gcaesthetics.com/
At Endomag, we believe everyone deserves a better standard of cancer care – that’s why we design our unique magnetic technologies with both the clinician and patient in mind. Many leading hospitals across the world use our solutions to help breast cancer patients avoid surgery when it isn’t needed, and experience better outcomes when it is.
Our Magseed® marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace® lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping. Paired with the Sentimag® localisation platform, they have now been widely proven across over 100 clinical studies, featuring more than 20,000 patients.
The Sentimag® platform has already helped 450,000+ women worldwide to access more precise and less invasive breast cancer treatment. Are you ready to join the magnetic revolution?
For more information, please visit visit www.endomag.com
Our Magseed® marker is a tiny, non-radioactive seed, ideal for accurately marking tumours and lymph nodes, while the Magtrace® lymphatic tracer is the world’s first, long-lasting, non-radioactive dual tracer for lymphatic mapping. Paired with the Sentimag® localisation platform, they have now been widely proven across over 100 clinical studies, featuring more than 20,000 patients.
The Sentimag® platform has already helped 450,000+ women worldwide to access more precise and less invasive breast cancer treatment. Are you ready to join the magnetic revolution?
For more information, please visit visit www.endomag.com
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information, please visit visit www.gilead.com
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
For more information, please visit visit www.gilead.com
Daiichi Sankyo UK and AstraZeneca UK: Combining collective expertise to push the boundaries of what is possible in cancer care. Our collaboration is based on a shared commitment to support patients.
The CoBrCa Conference 2024 is supported by the pharmaceutical industry through sponsorship and the purchase of exhibition space. Sponsoring companies have no influence or involvement in the preparation of this event.
UK/ADC/03/24/0021 | March 2024
The CoBrCa Conference 2024 is supported by the pharmaceutical industry through sponsorship and the purchase of exhibition space. Sponsoring companies have no influence or involvement in the preparation of this event.
UK/ADC/03/24/0021 | March 2024
Synapse Medical UK has solidified its position as the premier provider of Diagnostic Imaging services in both Ireland and the UK. With a widespread presence across these regions, our company boasts a team of dedicated employees, including a proficient group of Clinical Sales Specialists. Our commitment is steadfast when it comes to ensuring that our customers not only meet but exceed their expectations in terms of service. Synapse Medical UK are delighted to invite you to stand No: 24 to witness first hand, our new innovative diagnostic imaging products.
For more information, please visit www.synapsemedical.ie/
For more information, please visit www.synapsemedical.ie/
Establishment Labs® Holdings Inc. (NASDAQ: ESTA) is a global medical technology company focused on improving patient safety and aesthetic outcomes, initially in the breast aesthetics and reconstruction market by designing, developing, manufacturing and marketing an innovative portfolio of silicone gel-filled breast implants, branded as Motiva Implants®, the centerpiece of the MotivaImagine® platform.
Motiva Implants® are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs® received approval for an investigational device exemption (IDE) from the FDA to initiate the Motiva Implants® clinical trial in the United State. After more than a decade on the market, from 2010 to 2023, and 3 million implants sold, Motiva Implants® have consistently reported rates of less than 1 % device-related complications leading to reoperation.
For more information, please visit establishmentlabs.com/
Motiva Implants® are produced at two FDA compliant state-of-the-art facilities in Costa Rica and currently sold in over 80 countries through exclusive distributors or the Company’s direct salesforce. In March 2018, Establishment Labs® received approval for an investigational device exemption (IDE) from the FDA to initiate the Motiva Implants® clinical trial in the United State. After more than a decade on the market, from 2010 to 2023, and 3 million implants sold, Motiva Implants® have consistently reported rates of less than 1 % device-related complications leading to reoperation.
For more information, please visit establishmentlabs.com/
Agendia is a leading provider of innovative solutions in precision oncology, specializing in early-stage breast cancer. They offer reliable biological insights for personalized treatment decisions, using advanced genomic assays like MammaPrint® and BluePrint®. These assays help clinicians quickly identify the most effective treatment plan, reducing the risks of over- and under-treatment.
Founded in 2003 in Amsterdam, Agendia is headquartered in Irvine, California, with a state-of-the-art laboratory. Led by world-renowned scientists and oncologists, Agendia is dedicated to advancing genomic insights through ongoing research. Notably, their FLEX Study is the world’s largest Real-World Evidence-based Breast Cancer database, aiming to revolutionize precision in breast cancer management. With cutting-edge technology, research, and innovation, Agendia strives to shape the future of precision oncology and make a significant impact in the fight against breast cancer.
Disclaimer:
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
For more information, please visit www.agendia.com/
Founded in 2003 in Amsterdam, Agendia is headquartered in Irvine, California, with a state-of-the-art laboratory. Led by world-renowned scientists and oncologists, Agendia is dedicated to advancing genomic insights through ongoing research. Notably, their FLEX Study is the world’s largest Real-World Evidence-based Breast Cancer database, aiming to revolutionize precision in breast cancer management. With cutting-edge technology, research, and innovation, Agendia strives to shape the future of precision oncology and make a significant impact in the fight against breast cancer.
Disclaimer:
©2024 Agendia. All rights reserved. MammaPrint and Blueprint are registered trademarks of Agendia, Inc.
For more information, please visit www.agendia.com/
At Solventum, we enable better, smarter, safer healthcare to improve lives. We’re a new company with a long legacy of creating breakthrough solutions for our customers’ toughest challenges. Rooted in a history of diverse expertise with over 70+ years of expertise, we are a leader in the advanced wound care market (based on data from BCC Research report) and estimate that our products treat more than 1.6 million hard-to-heal wounds annually.
Our solutions are designed to accelerate healing, prevent complications and lower the total cost of care. With industry-leading products, education and support, Solventum helps you improve patient outcomes — and lead the way in healthcare.
Our solutions are designed to accelerate healing, prevent complications and lower the total cost of care. With industry-leading products, education and support, Solventum helps you improve patient outcomes — and lead the way in healthcare.
Founded in 1987, Merit Medical Systems, Inc. is a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care and endoscopy. Our Merit Oncology is the new standard of care in wireless localization. We help healthcare providers achieve better patient outcomes through clinical and cost effective care and drive progress through innovation, knowledge sharing and the latest scientific research. The SCOUT® Radar Localization system has been clinically demonstrated to drive value and improve patient outcomes. SCOUT is proven to improve radiology workflow and significantly reduce OR delays. This can mean more successful surgeries, optimized breast conservation strategies, and enhanced outcomes for women.
For more information, please visit www.merit.com/merit-oncology
For more information, please visit www.merit.com/merit-oncology
At Menarini Stemline, we are committed to developing a broad pipeline of innovative, transformative therapies in Oncology & Haematology and making a difference in cancer patients’ lives. We invest in developing precision medicine through our pipeline of investigational drugs and partner with cancer experts and research institutions globally. Stemline is part of the Menarini Group, a leading international pharmaceutical and diagnostics company
Address: MENARINI STEMLINE UK LTD, THE STANLEY BUILDING, SEVEN PANCRAS SQUARE, 7 KING’S BOULEVARD, LONDON N1C 4AG
Contact Number: 0203 007 9012
Contact Name: Jonathan Jones, Brand Lead – Oncology
Email Address – jjones@menarinistemline.com
Address: MENARINI STEMLINE UK LTD, THE STANLEY BUILDING, SEVEN PANCRAS SQUARE, 7 KING’S BOULEVARD, LONDON N1C 4AG
Contact Number: 0203 007 9012
Contact Name: Jonathan Jones, Brand Lead – Oncology
Email Address – jjones@menarinistemline.com
PreludeDx is the leading personalized breast cancer diagnostics company dedicated to improving outcomes for patients diagnosed with DCIS (Ductal Carcinoma in Situ). The company provides patients and physicians with evidence-based tools to improve patient outcomes and reduce the cost to the healthcare system by helping to ensure women are not over or under treated. For women diagnosed with DCIS, PreludeDx provides a patented molecular test (DCISionRT®) that predicts a woman’s personal likelihood or risk of developing DCIS recurrence in 10 years and invasive breast cancer in 10 years with or without adjuvant radiation therapy after breast conserving surgery.
For more information, please visit PreludeDx.com
For more information, please visit PreludeDx.com
APIS is leveraging systems biology and multi-OMICs biodata for validation and translation of biomarkers into clinical utility. Our breast oncology product portfolio is expanding: The APIS Breast Cancer Subtyping Kit is a reproducible RT-qPCR based IVD product (in certain territories) and RUO product for detecting standard (HER2, ER, PR, Ki67) and novel proliferative biomarkers. The APIS ESR1 Mutations Kit is a qPCR assay for the sensitive detection of eleven key mutations within the oestrogen receptor gene. Coming soon – the APIS PIK3CA Mutations Kit is a qPCR assay for detection of the 5 most prevalent mutations in the PIK3CA gene.
For more information, please visit www.apisassay.com/
For more information, please visit www.apisassay.com/
We’re Breast Cancer Now, the research and support charity. We’re here for everyone with breast cancer.
Alongside funding life-saving research and provide information and support, we work closely with healthcare professionals to make sure everyone affected by breast cancer gets the best treatment and care, when they need it.
Why? Because our vision is that by 2050, everyone diagnosed with breast cancer will live and be supported to live well. But to make that vision a reality, we need to act now.
For more information, please visit Breast Cancer Now | The research and support charity
Alongside funding life-saving research and provide information and support, we work closely with healthcare professionals to make sure everyone affected by breast cancer gets the best treatment and care, when they need it.
Why? Because our vision is that by 2050, everyone diagnosed with breast cancer will live and be supported to live well. But to make that vision a reality, we need to act now.
For more information, please visit Breast Cancer Now | The research and support charity